Preeclampsia risk assessment across all trimesters using blood-based biochemical markers

Hear from our subject matter experts about the latest breakthrough biomarkers to help in the risk assessment and clinical management of preeclampsia across U.S. patient populations in the first, second and third trimesters.

Speakers:

Sydney Strickland, PhD, DABCC
Clinical Laboratory Director, Biochemical Genetics Discipline Director, Women’s Health and Genetics

Kelly Curd, MS, MEd, CGC
Medical Science Liaison, Women’s Health and Genetics